| 查看: 2555 | 回复: 27 | |||
| 本帖产生 2 个 DRDEPI ,点击这里进行查看 | |||
| 当前只显示满足指定条件的回帖,点击这里查看本话题的所有回帖 | |||
狼行拂晓荣誉版主 (著名写手)
~~~~
|
[交流]
金秋之际话“丰收”,有奖分享经验总结活动,期待你的参与! 已有10人参与
|
||
|
金秋之际话“丰收”,有奖分享经验总结活动,期待你的参与!
【活动内容】
【活动目的】: [ Last edited by 狼行拂晓 on 2015-10-19 at 20:11 ] |
» 本帖已获得的红花(最新10朵)
» 猜你喜欢
070700求调剂
已经有1人回复
求调剂总分327
已经有1人回复
药理学论文润色/翻译怎么收费?
已经有128人回复
BL21(DE3)UV或者丝裂霉素诱导条件下会释放DE3的噬菌体吗?
已经有479人回复
NSCLC脑转移肿瘤模型
已经有0人回复
CHP-134这个细胞系哪里有?
已经有0人回复
27年环评考试资料
已经有1人回复
多糖提取纯化结构表征和活性
已经有0人回复
英国贝尔法斯特女王大学药物递送方向招CSC博士生
已经有1人回复
Materials Today Chemistry和AMH哪个投稿快啊
已经有0人回复

狼行拂晓
荣誉版主 (著名写手)
~~~~
- DRDEPI: 13
- 应助: 129 (高中生)
- 贵宾: 0.045
- 金币: 10341.8
- 散金: 619
- 红花: 57
- 帖子: 1289
- 在线: 877.3小时
- 虫号: 1037685
- 注册: 2010-06-07
- 性别: GG
- 专业: 药物化学
- 管辖: 新药研发
狼行拂晓: 回帖置顶 2015-11-05 16:49:45
|
相信论坛里做仿制药的相对多一点,FDA中关于Generic Drug的指导原则这么多,大家都可以就其中一篇发表下学习收获等…… Generic Drug Issued Date 180-Day Exclusivity When Multiple Abbreviated New Drug Applications Are Submitted on the Same Day (I) 8/1/2003 Abbreviated New Drug Applications: Impurities in Drug Products 11/29/2010 Alternate Source of Active Pharmaceutical Ingredients in Pending ANDAs (I) 12/12/2000 ANDAs: Impurities in Drug Substances; Chemistry, Manufacturing and Controls Information (I) 7/15/2009 ANDAs: Pharmaceutical Solid Polymorphism; Chemistry, Manufacturing and Controls Information (I) 7/9/2007 ANDAs: Stability Testing of Drug Substances and Products, Questions and Answers 5/15/2014 ANDA Submissions – Amendments and Easily 7/10/2014 ANDA Submissions – Prior Approval Supplements Under GDUFA 7/10/2014 ANDA Submissions -- Refuse-to-Receive Standards 9/16/2014 Controlled Correspondence Related to Generic Drug Development 8/26/2014 Court Decisions, ANDA Approvals, and 180-Day Exclusivity Under the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act (I) 3/30/2000 Handling and Retention of Bioavailability and Bioequivalence Testing Samples (I) 5/26/2004 Individual Product Bioequivalence Recommendations - List of Product Bioequivalence Recommendations (I) 6/11/2010 Letter announcing that the OGD will now accept the ICH long-term storage conditions as well as the stability studies conducted in the past (I)8/18/1995 Letter describing efforts by the CDER & the ORA to clarify the responsibilities of CDER chemistry review scientists and ORA field investigators in the new & abbreviated drug approval process in order to reduce duplication or redundancy in the process (I) 10/14/1994 Letter on incomplete Abbreviated Applications, Convictions Under GDEA, Multiple Supplements,Annual Reports for Bulk Antibiotics, Batch Size for Transdermal Drugs, Bioequivalence Protocols, Research, Deviations from OGD Policy (I) 4/8/1994 Letter on the provision of new information pertaining to new bioequivalence guidelines and refuse-to-file letters (I) 7/1/1992 Letter on the provision of new procedures and policies affecting the generic drug review process (I) 3/15/1989 Letter on the request for cooperation of regulated industry to improve the efficiency and effectiveness of the generic drug review process, by assuring the completeness and accuracy of required information and data submissions (I) 11/8/1991 Letter on the response to 12/20/84 letter from the Pharmaceutical Manufacturers Association about the Drug Price Competition and Patent Term Restoration Act (I) 3/26/1985 Letter to all ANDA and AADA applicants about the Generic Drug Enforcement Act of 1992 (GDEA), and the Office of Generic Drugs intention to refuse-to-file incomplete submissions as required by the new law (I) 1/15/1993 Letter to regulated industry notifying interested parties about important detailed information regarding labeling, scale-up, packaging, minor/major amendment criteria, and bioequivalence requirements (I) 8/4/1993 Major, Minor, and Telephone Amendments to Abbreviated New Drug Applications (I) 12/21/2001 Revising ANDA Labeling Following Revision of the RLD Labeling (I) 4/25/2000 Size, Shape, and Other Physical Attributes of Generic Tablets and Capsules 12/10/2013 Submission of Summary Bioequivalence Data for Abbreviated New Drug Applications (I) 5/6/2011 Variations in Drug Products that May Be Included in a Single ANDA (I) 1/27/1999 |

20楼2015-11-05 16:48:22
凌宇雷池
超级版主 (文学泰斗)
小木虫科研大使\(^o^)/~
- DRDEPI: 1
- 应助: 758 (博后)
- 贵宾: 165.138
- 金币: 309516
- 散金: 91930
- 红花: 1123
- 沙发: 3529
- 帖子: 93408
- 在线: 56182小时
- 虫号: 659100
- 注册: 2008-11-21
- 性别: GG
- 专业: 生物化学
- 管辖: 科研生活区

2楼2015-10-09 22:23:35
News
专家顾问 (职业作家)
- DRDEPI: 6
- 应助: 366 (硕士)
- 贵宾: 0.025
- 金币: 5936.5
- 散金: 3206
- 红花: 155
- 沙发: 24
- 帖子: 4829
- 在线: 677.6小时
- 虫号: 1205015
- 注册: 2011-02-17
- 性别: GG
- 专业: 色谱分析
- 管辖: 生物医药区

3楼2015-10-11 09:07:20
狼行拂晓
荣誉版主 (著名写手)
~~~~
- DRDEPI: 13
- 应助: 129 (高中生)
- 贵宾: 0.045
- 金币: 10341.8
- 散金: 619
- 红花: 57
- 帖子: 1289
- 在线: 877.3小时
- 虫号: 1037685
- 注册: 2010-06-07
- 性别: GG
- 专业: 药物化学
- 管辖: 新药研发

5楼2015-10-11 12:45:41












回复此楼
News